WO2015036643A3 - Marcador para predecir metástasis del cáncer de mama - Google Patents
Marcador para predecir metástasis del cáncer de mama Download PDFInfo
- Publication number
- WO2015036643A3 WO2015036643A3 PCT/ES2014/070699 ES2014070699W WO2015036643A3 WO 2015036643 A3 WO2015036643 A3 WO 2015036643A3 ES 2014070699 W ES2014070699 W ES 2014070699W WO 2015036643 A3 WO2015036643 A3 WO 2015036643A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- breast cancer
- taxane
- metastasis
- marker
- vitro method
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La invención se relaciona con un método in vitro para predecir metástasis en un sujeto diagnosticado con cáncer de mama y tratado con un taxano, con un método in vitro para la selección de pacientes de cáncer de mama que presentan riesgo de desarrollar metástasis tras el tratamiento con taxano y con un método in vitro para el diseño de una terapia personalizada de un sujeto que sufre de cáncer de mama y que está siendo tratado con taxano basados en determinar el nivel de GRP94 y/o FN14. Asimismo, la invención se relaciona con una composición que comprende un taxano y un inhibidor de GRP94 y/o un inhibidor de FN14 y con su uso en el tratamiento de metástasis cerebral.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/021,134 US20160223547A1 (en) | 2013-09-13 | 2014-09-12 | Marker for predicting metastasis of breast cancer |
EP14789584.1A EP3045917A2 (en) | 2013-09-13 | 2014-09-12 | Marker for predicting metastasis of breast cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201331335 | 2013-09-13 | ||
ESP201331335 | 2013-09-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2015036643A2 WO2015036643A2 (es) | 2015-03-19 |
WO2015036643A3 true WO2015036643A3 (es) | 2015-06-04 |
Family
ID=51795644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2014/070699 WO2015036643A2 (es) | 2013-09-13 | 2014-09-12 | Marcador para predecir metástasis del cancer de mama |
Country Status (3)
Country | Link |
---|---|
US (1) | US20160223547A1 (es) |
EP (1) | EP3045917A2 (es) |
WO (1) | WO2015036643A2 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018134254A1 (en) | 2017-01-17 | 2018-07-26 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
BR112020000477A2 (pt) | 2017-07-10 | 2020-07-21 | Cornell University | ataque à instabilidade cromossômica e sinalização de dna citosólico a jusante para tratamento de câncer |
CN113881769B (zh) * | 2021-06-03 | 2023-08-18 | 南京世和基因生物技术股份有限公司 | 脑脊液cfDNA在用于乳腺癌转移诊疗中的用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005000314A1 (en) * | 2003-05-30 | 2005-01-06 | Kosan Biosciences, Inc. | Method for treating diseases using hsp90-inhibiting agents in combination with antimitotics |
WO2005046593A2 (en) * | 2003-11-06 | 2005-05-26 | Celgene Corporation | Methods and compositions using thalidomide for the treatment and management of cancers and other diseases. |
WO2010142651A2 (en) * | 2009-06-10 | 2010-12-16 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge (Idibell) | Method for determining the risk of developing brain metastasis, and a kit to carry out said method |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
US20090186039A1 (en) | 2008-01-18 | 2009-07-23 | Jang Sung-Key | Novel use of grp 94 in virus infection |
MX2010012324A (es) | 2008-05-15 | 2011-01-14 | Biogen Idec Inc | Anticuerpos anti-fn14 y usos de los mismos. |
US8686165B2 (en) | 2009-11-04 | 2014-04-01 | Emcure Pharmaceuticals Limited | Process for preparation of taxane derivatives |
US8771687B2 (en) | 2010-12-02 | 2014-07-08 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods for treating a tumor using an antibody that specifically binds GRP94 |
-
2014
- 2014-09-12 EP EP14789584.1A patent/EP3045917A2/en not_active Withdrawn
- 2014-09-12 WO PCT/ES2014/070699 patent/WO2015036643A2/es active Application Filing
- 2014-09-12 US US15/021,134 patent/US20160223547A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005000314A1 (en) * | 2003-05-30 | 2005-01-06 | Kosan Biosciences, Inc. | Method for treating diseases using hsp90-inhibiting agents in combination with antimitotics |
WO2005046593A2 (en) * | 2003-11-06 | 2005-05-26 | Celgene Corporation | Methods and compositions using thalidomide for the treatment and management of cancers and other diseases. |
WO2010142651A2 (en) * | 2009-06-10 | 2010-12-16 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge (Idibell) | Method for determining the risk of developing brain metastasis, and a kit to carry out said method |
Non-Patent Citations (1)
Title |
---|
TOSONI A ET AL: "Chemotherapy in breast cancer patients with brain metastases: Have new chemotherapic agents changed the clinical outcome?", CRITICAL REVIEWS IN ONCOLOGY / HEMATOLOGY, ELSEVIER SCIENCE IRELAND LTD., LIMERICK, IE, vol. 68, no. 3, 1 December 2008 (2008-12-01), pages 212 - 221, XP025780311, ISSN: 1040-8428, [retrieved on 20080612], DOI: 10.1016/J.CRITREVONC.2008.04.004 * |
Also Published As
Publication number | Publication date |
---|---|
US20160223547A1 (en) | 2016-08-04 |
EP3045917A2 (en) | 2016-07-20 |
WO2015036643A2 (es) | 2015-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022006075A (es) | Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer. | |
PH12016501728A1 (en) | Anti-angiogenesis therapy for the treatment of ovarian cancer | |
WO2015189345A3 (en) | Compositions and methods for the diagnosis and treatment of bone fractures and disorders | |
PH12015501744A1 (en) | Therapeutic and diagnostic target for cancer comprising dll3 binding reagents | |
MX2020010947A (es) | Metodos de tratamiento de enfermedad de alzheimer. | |
PH12020551683A1 (en) | Biomarkers for graft-versus-host disease | |
EP4356960A3 (en) | Biomarkers and methods of treating pd-1 and pd-l1 related conditions | |
WO2014143807A3 (en) | Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders | |
PH12016502167A1 (en) | Hdl theraphy markers | |
MX2018004170A (es) | Biomarcadores relacionados con enfermedades mediadas por interleucina-33 (il-33) y usos de los mismos. | |
MX2015009392A (es) | Biomarcadores de terapia de combinacion anti-tnf y anti-il17 para enfermedades inflamatorias. | |
BR112016007864A2 (pt) | método para a prognose e tratamento de metástase de câncer | |
EP4321866A3 (en) | Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers | |
EP4279127A3 (en) | Growth differentiation factor 15 as biomarker for metformin | |
WO2014205266A3 (en) | Compositions and methods for detecting and treating glioblastoma | |
WO2015116729A3 (en) | Anti-cd37 antibody and anti-cd20 antibody combination therapy for treatment of b-cell malignancies and disorders | |
MX2018001831A (es) | Biomarcadores para el tratamiento de alopecia areata. | |
WO2016030334A3 (en) | Methods, agents and compositions for treatment of inflammatory conditions | |
MX2015012444A (es) | Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos. | |
MX2016017097A (es) | Biomarcadores para la respuesta a inhibidores del mejorador del homologo 2 de zeste (ezh2). | |
MX2020006388A (es) | Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea. | |
WO2015036643A3 (es) | Marcador para predecir metástasis del cáncer de mama | |
BR112014018374A8 (pt) | Método para predizer a resposta d eum paciente com câncer, kit, anticorpo, método para o tratamento do câncer e composição farmacêutica | |
MX2021011799A (es) | Antagonistas de semaforina 4d para usarlos en la terapia contra el cancer. | |
WO2013171777A3 (en) | Use of trop-2 as predictive marker of response to anti-tumor therapy based on inhibitors of cd9, akt and molecules of the tetraspanin signalling network |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14789584 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15021134 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2014789584 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014789584 Country of ref document: EP |